GUANGZHOU, China, May 14, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") $(POM)$, a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Fiscal year 2025 marked a year of solid revenue expansion and continued execution of our growth strategy. Both our net revenues and gross profit recorded solid year-over-year increases, by 16.7% and 9.6% respectively, primarily driven by the strong growth of our Internet hospital business, particularly online pharmacy sales as we deepened collaboration with pharmaceutical manufacturers. At the same time, we achieved a steady gross margin over 13%, reflecting our capability in maintaining profit while continuing expansion of our business scale, executing sales promotions and obtaining new customers.

"During the year, we also increased our investments in research and development ("R&D") by 328.5% to support our long-term strategic priorities. Our R&D efforts are focused on enhancing our technology-driven healthcare capabilities and strengthening our platform infrastructure, which we believe will enable us to deliver more efficient and accessible healthcare services while supporting sustainable growth over time.

"Despite the net loss for the year, which was primarily attributable to significant non-recurring expenses associated with our initial public offering, including professional service fees and investor relations initiatives, we view these costs as necessary and strategic investments. These investments enabled our transition to a publicly listed company, strengthened our corporate governance, enhanced our operational and financial capabilities, and unlocked broader growth opportunities for the future. Following our successful listing, we are now better positioned to access capital market resources to support business expansion and execute our long-term growth strategy more efficiently on a larger scale.

"Looking ahead, we remain confident in the long-term growth potential of China's digital healthcare market. We will continue to deepen strategic partnerships with pharmaceutical companies to further drive Internet hospital growth, accelerate the integration of our platform with online medical insurance systems across major cities, and advance our strategic upgrade centered on 'artificial intelligence (AI) + medical-grade smart wearables + full-cycle chronic disease management.' We believe these initiatives will strengthen our ecosystem and position us for scalable growth and long-term value creation."

Fiscal Year 2025 Financial Summary

   -- Net revenues were RMB399.9 million (US$57.2 million) in fiscal year 2025, 
      an increase of 16.7% from RMB342.6 million in fiscal year 2024. 
 
   -- Gross profit was RMB52.3 million (US$7.5 million) in fiscal year 2025, an 
      increase of 9.6% from RMB47.7 million in fiscal year 2024. 
 
   -- Gross margin was 13.1% in fiscal year 2025, compared to 13.9% in fiscal 
      year 2024. 
 
   -- Net loss was RMB130.9 million (US$18.7 million) in fiscal year 2025, 
      compared to RMB37.4 million in fiscal year 2024. 
 
   -- Basic and diluted loss per share were RMB21.96 (US$3.14) in fiscal year 
      2025, compared to RMB22.72 in fiscal year 2024. 

Fiscal Year 2025 Financial Results

Net Revenues

Net revenues were RMB399.9 million (US$57.2 million) in fiscal year 2025, an increase of 16.7% from RMB342.6 million in fiscal year 2024.

   -- Net revenues from Internet hospital were RMB150.7 million (US$21.6 
      million) in fiscal year 2025, an increase of 69.3% from RMB89.0 million 
      in fiscal year 2024. The increase was primarily due to the increase in 
      revenues generated from online pharmacy sales. In fiscal year 2025, the 
      Company deepened cooperation with pharmacy manufacturers to sell their 
      products through its Internet hospital platform, which led to that 
      revenue from the Company's online pharmacy sales increased from RMB87.8 
      million in fiscal year 2024 to RMB149.2 million (US$21.3 million) in 
      fiscal year 2025. Revenue from online consultation service slightly 
      increased from RMB1.2 million in fiscal year 2024 to RMB1.5 million 
      (US$0.2 million) in fiscal year 2025. 
 
   -- Net revenues from pharmaceutical supply chain were RMB249.2 million 
      (US$35.6 million) in fiscal year 2025, a decrease of 1.7% from RMB253.5 
      million in fiscal year 2024, primarily driven by the decrease in the 
      Company's pharmacy wholesale business from RMB246.9 million in fiscal 
      year 2024 to RMB243.2 million (US$34.8 million) in fiscal year 2025, as a 
      result of the Company's stable pharmaceutical supply chain business and 
      reduction cooperation with the customers whose credit terms were 
      relatively longer than others. Because of high competition of retail 
      pharmacy store, two of the Company's retail sales stores were closed in 
      fiscal year 2025, which led to that the revenues from pharmacy retail 
      sales also decreased from RMB6.6 million in fiscal year 2024 to RMB6.0 
      million (US$0.9 million) in fiscal year 2025. 

Cost of Revenues

Cost of revenue was RMB347.6 million (US$49.7 million) in fiscal year 2025, an increase of 17.9% from RMB294.9 million in fiscal year 2024. The increase was primarily due to the increase in cost of revenues in online pharmacy sales from RMB51.0 million in fiscal year 2024 to RMB101.4 million (US$14.5 million) in fiscal year 2025, which was in line with the increase in the Company's net revenues from Internet hospital. The cost of revenues in pharmaceutical supply chain increased from RMB243.9 million in fiscal year 2024 to RMB246.2 million (US$35.2 million) in fiscal year 2025.

Gross Profit and Gross Margin

Gross profit was RMB52.3 million (US$7.5 million) in fiscal year 2025, an increase of 9.6% from RMB47.7 million in fiscal year 2024.

Gross margin was 13.1% in fiscal year 2025, slightly decreased from 13.9% in fiscal year 2024.

   -- Gross profit margin of Internet hospital was 32.7% in fiscal year 2025, 
      decreased from 42.7% in fiscal year 2024. The decrease mainly 
      attributable to the increase in the online pharmacy sales of products 
      with lower gross profit margin. 
 
   -- Gross profit margin of pharmaceutical supply chain was 1.2% in fiscal 
      year 2025, decreased from 3.8% in fiscal year 2024. The decrease was 
      primarily because the gross profit margin of the Company's pharmacy 
      wholesale customers newly obtained in fiscal year 2025 was lower than 
      that of customers in fiscal year 2024. 

Operating Expenses

Total operating expenses were RMB170.9 million (US$24.4 million) in fiscal year 2025, compared to RMB73.5 million in fiscal year 2024.

   -- Sales and marketing expenses were RMB96.2 million (US$13.8 million) in 
      fiscal year 2025, increased by 70.7% from RMB56.4 million in fiscal year 
      2024. The increase primarily due to the increase in professional service 
      fees paid to outsourced consultants for promoting the Company's brand and 
      internet medical platform of approximately RMB36.5 million (US$5.2 
      million) and service fees to doctors and staff costs which is in line of 
      the increase in the revenues from Internet hospital business. 
 
   -- General and administrative expenses were RMB59.7 million (US$8.5 million) 
      in fiscal year 2025, increased by 402.9% from RMB11.9 million in fiscal 
      year 2024. The increase primarily due to (i) increase in professional 
      service fee paid to outsourced consultants for consultancy for investor 
      relationship management of approximately RMB38.0 million (US$5.4 million) 
      incurred in fiscal year 2025; and (ii) the increase in consulting service 
      fee and office fees of RMB6.5 million (US$0.9 million) paid during the 
      process of initial public offering, primarily offset by the decrease in 
      expected credit loss recognized resulting from the efforts for collection 
      of accounts receivable. 
 
   -- Research and development expenses were RMB12.9 million (US$1.8 million) 
      in fiscal year 2025, increased by 328.5% from RMB3.0 million in fiscal 
      year 2024. The increase primarily due to a new research and development 
      project, especially in AI and healthcare-related AI applications, 
      launched in fiscal year 2025 and related consulting service fee paid. 
 
   -- Impairment loss on property and equipment and operating lease 
      right-of-use assets with definite lives of RMB2.2 million and RMB2.1 
      million (US$0.3 million) in fiscal year 2024 and 2025, respectively. 

Net Loss

Net loss was RMB130.9 million (US$18.7 million) in fiscal year 2025, compared to RMB37.4 million in fiscal year 2024.

Basic and Diluted Loss per Share

Basic and diluted loss per share were RMB21.96 (US$3.14) in fiscal year 2025, compared to RMB22.72 in fiscal year 2024.

Financial Condition

As of December 31, 2025, the Company had cash and cash equivalents of RMB9.6 million (US$1.4 million), compared to RMB7.7 million as of December 31, 2024.

Net cash used in operating activities in fiscal year 2025 was RMB148.5 million (US$21.2 million), compared to RMB16.1 million in fiscal year 2024.

Net cash used in investing activities in fiscal year 2025 was RMB1.6 million (US$0.2 million), compared to RMB0.03 million in fiscal year 2024.

Net cash provided by financing activities in fiscal year 2025 was RMB153.9 million ($22.0 million), compared to RMB17.0 million in fiscal year 2024.

Exchange Rate Information

(MORE TO FOLLOW) Dow Jones Newswires

May 14, 2026 16:30 ET (20:30 GMT)